



www.G2Gconsulting.com

Government Bioscience Grant (GBG) Report
April 2017

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Eligibility	Link
			BROAD AGENCY ANNOUNCEMENTS				
1.	Fiscal Year 2018 Air Force Young Investigator Research Program (YIP) (Air Force/DOD)	BAA-AFRL-AFOSR-2017-0002	The Fiscal Year 2018 Air Force Young Investigator Research Program (YIP) intends support for scientists and engineers demonstrating exceptional ability and promise for conducting basic research who have:1. Received a Ph.D. or equivalent degree on 1 April 2012 or later; or, (2) Received a Ph.D. or equivalent degree between 1 April 2010 and 1 April 2012, be presently in a tenure-track position and have served as a tenure-track faculty member for no more than two years prior to 01 April 2017.	Full Proposal Due: 6/1/17	Up to \$450,000	Received a Ph.D. or equivalent degree on 1 April 2012 or later	https://www.grants.gov/web/grants/view-opportunity.html?oppId=292986
2.	DARPA Biological Technologies Office Open BAA	HR001117S0030	DARPA is soliciting innovative research proposals of interest to the Biological Technologies Office (BTO). Proposed research should investigate leading edge approaches that enable revolutionary advances in science, technologies, or systems at the intersection of biology with engineering and the physical and computer sciences. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of the art. BTO seeks unconventional approaches that are outside the mainstream, challenge assumptions, and have the potential to radically change established practice, lead to extraordinary outcomes, and create entirely new fields.	Open until 4/26/2018	Dependent upon proposal	Unrestricted	https://www.fbto.gov/index?s=opportunity&mode=form&id=91b94156bbad11c1cb1b8a8873510ed3&tab=core&_cvview=0

			CANCER				
3.	Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 and Collaborative R01) (NIH)	PAR-17-245 PAR-17-244	This FOA invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally	Full Proposal Due: 6/5/17	Up to \$450,000 per year for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-245.html
4.	Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01) (NIH)	PAR-16-111	The purpose of this FOA is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy.	Letter of Intent Due: 5/30/17 Full Proposal Due: 7/14/17	Up to \$450,000 per year for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-16-111.html
			CELLULAR/ REGENERATIVE MEDICINE				
5.	Novel Cell Non-autonomous Mechanisms of Aging (R01) (NIH)	RFA-AG-18-009	The goal of this FOA is to support applications that will lead to in-depth understanding of the mechanisms that produce cell non-autonomous aging signals: what they are, how they are generated from cell autonomous aging, how they are released from cells, how they are transported or communicated to other cells, and how they elicit aging upon reaching their target cells.	Letter of Intent Due: 9/3/17 Full Proposal Due: 10/3/17	Up to \$250,000 per year for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-18-009.html

6.	Revision Applications for Regenerative Medicine Innovation Projects (RMIP)	RFA-HL-17-029	The NIH and participating NIH Institutes and Centers (ICs) and the FDA, through this Funding Opportunity Announcement, invite revision applications, from investigators with active research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.	Letter of Intent Due: 5/26/17 Full Proposal Due: 6/26/17	Up to \$324,500 for 1 year	Previous awardees with active projects open	https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-17-029.html
			GENOMICS				
7.	Integrative Computational Biology for Analysis of NHLBI TOPMed Data (R01)	RFA-HL-18-020	The purpose of this FOA is to support integrated analysis of whole genome, large scale “omic” data generated by the NHLBI’s Trans-Omics for Precision Medicine (TOPMed) program and associated phenotype and clinical data using systems approaches. Ultimately, these studies will advance our understanding of the molecular underpinnings of heart, lung, blood, and sleep disease.	Letter of Intent Due: 6/6/17 Full Proposal Due: 7/6/17	Up to \$324,000 per year for up to 2 years	Unrestricted	https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-18-020.html
			HEALTH IT/ DATA ANALYTICS				
8.	Implementation and Evaluation of New Health Information Technology (IT) Strategies for Collecting and Using Patient-Reported Outcome (PRO) Measures (U18) (AHRQ)	PA-17-247	This FOA invites U18 cooperative agreement applications to stimulate innovative and collaborative research by utilizing new health information technology (IT) strategies for collecting and using patient-reported outcome (PRO) measures in primary care and other ambulatory care settings.	Full Proposal Due: 9/25/17	Up to \$400,000 per year, with a max of \$1.2 million, for up to 3 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-17-247.html

9.	Health Information Technology (IT) to Improve Health Care Quality and Outcomes (R21) (AHRQ)	PA-17-246	This FOA issued by AHRQ invites grant applications for funding to conduct exploratory and developmental research grants (R21) for projects in the early and conceptual stages of development that will contribute to the evidence base of how health information technology (IT) improves health care quality and outcomes.	Full Proposal Due: 6/16/17	Up to \$200,000 per year, with a max of \$300,000, for up to 2 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-17-246.html
10.	State Vital Statistics Improvement Program (CDC)	CDC-RFA-SH17-1700	The CDC intends to establish a cooperative agreement with an organization with established relationships with all state, territorial and city vital statistics offices to enhance the performance of the National Vital Statistics System (NVSS). Vital statistics data are provided through contracts between the National Center for Health Statistics (NCHS) and the jurisdictions legally responsible for the registration of births, deaths, fetal deaths, marriages and divorces. The purpose of this funding opportunity is to enhance the performance of the NVSS by convening states to aid in a) improving vital statistics data quality, timeliness and public health utility, b) increasing the competencies of the vital statistics workforce, and c) promoting accreditation of jurisdictional vital statistics programs consistent with NCHS goals.	6/23/2017	Total award: \$3,472,500 over 5 years	Unrestricted	https://www.grants.gov/web/grants/view-opportunity.html?oppId=291278
11.	mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R01) (NIH/ NIBIB, NINR, NICHD)	PA-14-180	The purpose is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations. These mHealth tools may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress and may improve health outcomes. This announcement encourages the development, testing and comparative effective analysis of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations.	Letter of Intent Due: 9/5/17 Full Proposal Due: 10/5/17 Open until 1/8/2018	Dependent upon proposal, for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-14-180.html

			IMMUNOLOGY				
12.	Exploratory/ Developmental Investigations on Primary Immunodeficiency Diseases (R21) (NIH)	PA-16- 373	This FOA will support innovative exploratory/developmental investigations on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research.	Full Proposal Due: 6/16/17	Up to \$200,000 per year, with a max of \$275,000, for up to 2 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-16-373.html
13.	Small Grants on Primary Immunodeficiency Diseases (R03) (NIH)	PA-16- 372	Same as above, through the RO3 funding mechanism. The R03 grant supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources.	Full Proposal Due: 6/16/17	Up to \$50,000 per year for up to 2 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-16-372.html
			NANOTECHNOLOGY				
14.	Biological and Environmental Interactions of Nanoscale Materials (NSF)	PD 18- 1179	The goal of the Biological and Environmental Interactions of Nanoscale Materials program is to support research to advance fundamental and quantitative understanding of the interactions of biological and environmental media with nanomaterials and nanosystems. Materials of interest include one- to three-dimensional nanostructures, heterogeneous nano-bio hybrid assemblies, and other nanoparticles. Such nanomaterials and systems frequently exhibit novel physical, chemical, and biological behavior in living systems and environmental matrices as compared to the bulk scale.	No Deadline - Proposals for this program will be accepted throughout the year.	Up to \$100,000 per year for up to 3 years	Unrestricted	https://www.nsf.gov/funding/pgm_summ.jsp?pid=505424

NEURAL SYSTEMS							
15.	Pre-application: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Comprehensive Functional Mapping of Neuroanatomy and Neurobiology of Organs (OT1) (NIH)	RFA-RM-15-003	The purpose of this FOA is to invite pre-applications from applicants who have an interest in ultimately submitting an application to "Stimulating Peripheral Activity to Relieve Conditions (SPARC – see below.) The OT1 SPARC OT pre-application is the required first step in the application process for the companion OT2 FOA. Potential applicants should read both FOAs.	Full Proposal Due: 7/14/17	N/A	Unrestricted	https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-15-003.html
16.	Limited Competition - Stimulating Peripheral Activity to Relieve Conditions (SPARC): Comprehensive Functional Mapping of Neuroanatomy and Neurobiology of Organs (OT2) (NIH)	RFA-RM-15-018	Companion FOA to the FOA listed above. The purpose of this FOA is to invite applications (via limited competition) for SPARC Comprehensive Functional Mapping of Neuroanatomy and Neurobiology of Organs. These projects will comprehensively provide data for developing detailed, predictive functional and anatomical neural circuit maps for neural control of major functions of organs and their functionally-associated structures. Each project is to focus on a specific organ and the afferent and efferent innervation that controls function of the organ.	Full proposal deadline indicated upon receiving Invitation to Submit Full Proposal	Up to \$2 million per year for up to 3 years	Must be invited to submit proposal after pre-application process.	https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-15-018.html
17.	NINDS Program Project Grant (P01) (NIH)	PAR-17-251	This FOA is issued by NINDS to enable submission of program project grant applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.	Full Proposal Due: 5/25/17	Dependent upon proposal, for up to 5 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-251.html

18.	Neurobiology of Migraine (R21) (NIH)	PA-14-069	This FOA is issued by NINDS in conjunction with the NIH Pain Consortium. It solicits R21 grant applications from institutions/organizations to perform innovative research that will elucidate the mechanisms underlying migraines, expand our current knowledge of the role of genetic, physiological, biopsychosocial, and environmental influences in migraine susceptibility and progression, and explore new therapeutic targets and therapies for acute migraine management and longer term prevention.	Full Proposal Due: 6/16/17	Up to \$200,000 per year, with a max of \$275,000, for up to 2 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-14-069.html
19.	Translational Outcomes Project in Neurotrauma (TOP-NT) (UG3/UH3) (NIH)	RFA-NS-17-023	The purpose of this FOA is to support the development and validation of pathophysiologically based preclinical outcome measures or functional markers that align closely with practical clinical assessments in spinal cord injury (SCI) and/or traumatic brain injury (TBI). Bedside knowledge and experience will be leveraged to create better assessment tools for preclinical studies, and the resulting data will be made available to researchers. The goal is to improve the value of preclinical studies to inform clinical diagnoses and prognoses and therapeutic translation.	Letter of Intent Due: 7/21/17 Full Proposal Due: 8/21/17	UG3 Phase: Up to \$250,000 per year for up to 2 years UG3 Phase: Up to \$300,000 for up to 3 years	Unrestricted	https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-17-023.html
20.	From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (R01) (NIH)	PAR-17-253	The primary objective of this FOA is to stimulate innovative Convergent Neuroscience (CN) approaches to establish causal and/or probabilistic linkages across contiguous levels of analysis (e.g., gene, molecule, cell, circuit, system, and behavior) in an explanatory model of psychopathology. In particular, applicants should focus on how specific constituent biological processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomena. Although not required, it is preferable that applications link at least three levels of analysis and include an emphasis on genetics.	Full Proposal Due: 6/5/17	Up to \$500,000 per year for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-253.html

21.	Innovative Mental Health Services Research Not Involving Clinical Trials (R01) (NIH/NIMH)	PAR-17-264	The purpose is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services for patients with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities for mental health services research.	Letter of Intent Due: 9/5/2017 Full Proposal Due: 10/5/2017	Dependent upon application, for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-264.html
			PALLIATIVE CARE				
22.	Limited Competition: Palliative Care Research Cooperative (PCRC) (U2C) (NIH)	RFA-NR-17-001	The purpose of this FOA is to continue support for the research and resource activities of the Palliative Care Research Cooperative (PCRC); and facilitate cutting edge end-of-life and palliative care (EOLPC) research studies that need to be conducted with nationally representative samples and multiple sites.	Letter of Intent Due: 7/15/17 Full Proposal Due: 8/15/17	Up to \$1 million per year for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/rfa-files/RFA-NR-17-001.html# 3. Additional Information
			PHARMACEUTICALS				
23.	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33) (NIH)	PAR-15-071	This FOA provides funding to conduct pharmacodynamics, pharmacokinetics, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for NINDS Cooperative Research to Enable and Advance Translational Enterprises program (CREATE) for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational program.	Full Proposal Due: 6/16/17	R21 Phase: Up to \$250,000 per year for up to 2 years R33 Phase: Up to \$500,000 for up to 2 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-15-071.html

24.	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33) (NIH)	RFA-NS-16-013	This FOA encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, testing paradigms, and endpoints that will be utilized to facilitate the development of neurotherapeutics.	Full Proposal Due: 6/21/17	R21 Phase: Up to \$250,000 per year for up to 2 years R33 Phase: Up to \$250,000 for up to 2 years	Unrestricted	https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-16-013.html
SBIR/STTR							
25.	Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42 and R43/44) (NIH)	PA-14-171 PA-14-172	This FOA encourages STTR grant applications from SBCs that propose to develop technologies and approaches (i.e., novel ways to use new or existing technologies) that will enable researchers to study the structure and/or function of brain localized G-protein coupled receptor proteins (GPCRs) and/or potentially identify novel selective and specific agonists/antagonists to these receptor subtypes, with a focus on mental health function or dysfunction, including HIV-related neurocognitive disorders. Technologies and approaches aimed at known receptor subtypes or orphan receptors would be of potential interest to NIMH.	Full Proposal Due: 9/5/17	Phase 1: Up to \$150,000 per year for up to 2 years Phase II: Up to \$1 million for up to 3 years	Small Businesses	https://grants.nih.gov/grants/guide/pa-files/PA-14-171.html https://grants.nih.gov/grants/guide/pa-files/PA-14-172.html
26.	Complex Technologies and Therapeutics Development for Mental Health Research and Practice (R41/R42) (NIH)	PA-14-196	This STTR program at the NIMH aims to support small businesses to develop technologies that can advance the mission of the Institute, including basic neuroscience research relevant to mental disorders, translational and clinical research of mental disorders, clinical diagnosis or treatment of mental disorders, and dissemination of evidence-based mental health care. This FOA encourages STTR grant applications to support research and development of particular priority research topics - complex technologies that require funding levels and durations beyond those reflected in the standard STTR guidelines.	Full Proposal Due: 9/5/17	Phase 1: Up to \$150,000 per year for up to 2 years Phase II: Up to \$1 million for up to 3 years	Small Businesses	https://grants.nih.gov/grants/guide/pa-files/PA-14-196.html

27.	Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (SBIR) (R43) (NIH)	RFA-AR-18-005	This FOA solicits SBIR grant applications from SBCs that propose preclinical studies to advance the development of biomarkers or treatments for rare musculoskeletal, rheumatic or skin diseases. Also eligible for potential funding through this initiative are studies of FDA-designated orphan products for musculoskeletal, rheumatic or skin diseases.	Letter of Intent Due: 6/10/17 Full Proposal Due: 7/10/17	Up to \$225,000 per year for up to 1 year	Small Businesses	https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-18-005.html
28.	Nasal Delivery of CNS Therapeutics (R43/R44 and R41/42) (NIH)	RFA-DA-18-006 RFA-DA-18-007	The purpose of this STTR RFA is to develop a nasal delivery formulation that reliably delivers of a therapeutic (e.g., peptides, antibodies, RNAi, or pharmacotherapeutics), at a physiologically relevant concentration, into the central nervous system (CNS).	Letter of Intent Due: 7/24/17 Full Proposal Due: 8/23/17	Phase I: Up to \$150,000 per year for up to 6 months Phase II: Up to \$1 million for up to 2 years	Small Businesses	https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-18-006.html https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-18-007.html
29.	DoD SBIR 17.B and 17.2 BAA Pre-Solicitation		The DoD has pre-released its SBIR/STTR BAA. This SBIR includes topics of interest ranging from medical simulation technologies, health IT and pharmacokinetics, to point of care diagnostics, wearable monitoring devices and medical grade oxygen generation. Between this time and the date of the official solicitation, applicants are encouraged to speak with the technical points of contact (TPOCs), but may no longer do so once the window for application submission is open.	Proposal window: 5/23/17-6/21/17	Phase I: Up to \$150,000 for up to a year Phase II: Up to \$1 million for up to 2 years	Small Businesses	https://sbir.defensebusiness.org/topics/instructions

			SUBSTANCE ABUSE				
30.	Extracellular Vesicles and Substance Use Disorders (R21)	PAR-17-242	The purpose of this FOA is to encourage research projects that investigate the interplay between extracellular vesicles (EVs) and substance use disorders (SUDs). In particular, NIDA is interested in the potential utility of EVs with respect to understanding neuroplastic mechanisms relevant to SUDs or as biomarkers or therapeutics.	Letter of Intent Due: 7/15/17 Full Proposal Due: 8/15/17	Up to \$200,000 per year, with a max of \$275,000, for up to 2 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PAR-17-242.html
31.	Expanding Medication Assisted Treatment for Opioid Use Disorders in the Context of the SAMHSA Opioid STR Grants (R21/R33) (NIH)	RFA-DA-18-005	The purpose of this FOA is to solicit applications proposing to test approaches for expanding medication assisted treatment (MAT) for opioid use disorder (OUD) in the general health care sector or linking individuals with OUDs who receive naloxone for the reversal of overdose to MAT in the context of states' plans for use of the funds authorized under the 21st Century Cures Act.	Letter of Intent Due: 5/20/17 Full Proposal Due: 6/20/17	R21 Phase: Up to \$200,000 per year for up to 1 year R33 Phase: Up to \$500,000 for up to 3 years	Unrestricted	https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-18-005.html
32.	Effects of Cannabis Use and Cannabinoids on the Developing Brain (R03, R01, and R21) (NIH)	PA-14-164 PA-14-163 PA-14-162	This FOA encourages Small Research Grant (R03) applications from institutions and organizations that propose to study the effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri-, post-natal development through young adulthood in animal models and humans. Topics of interest pertaining to this PA include, but are not limited to: molecular and cellular mechanisms of cannabis/cannabinoid effects on the developing brain; long term functional consequences of cannabis/cannabinoid exposure on learning and memory, cognitive and emotional development.	Full Proposal Due: 6/16/17	Up to \$50,000 per year, with a max of \$100,000, for up to 2 years.	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-14-164.html

			OTHER				
33.	Obesity and Asthma: Awareness and Self-Management (R01) (NIH/NINR)	PA-14-316	The purpose of this funding opportunity announcement is to stimulate research to examine the relationship between asthma, obesity and self-management. Studies that investigate the molecular pathways linking asthma and obesity are encouraged as long as the studies describe how this relates to self-management. In addition, intervention studies targeting asthma or obesity and their effects on each other, and possible mechanisms of action and effect on behavior, are encouraged.	Letter of Intent Due: 9/5/2017 Full Proposal Due: 10/5/17 Opp. Open until: 1/8/2018	Dependent upon application, for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-14-316.html
34.	Community Partnerships to Advance Research (CPAR) (R01) (NIH)	PA-14-142	This funding opportunity addresses the need for researchers to partner with communities using Community Engaged Research methodologies that will enhance relationships leading to better interventions and positive health outcomes. Community Engagement (CE) lies on a continuum that reflects the level of involvement of community members, or representatives of community populations, in research. CE can take many forms, and partners can include community based groups, agencies such as the Center for Medicare and Medicaid Services (CMS) innovation centers, Centers for Disease Control and Prevention (CDC) prevention Research Centers, Health Resources and Services Administration (HRSA) Community Health Centers (CHC) and Federally Qualified Health Centers (FQHC), other academic health institutions, or individuals. Collaborators may be engaged in health promotion/prevention, clinical or intervention research.	Letter of Intent Due: 9/5/2017 Full Proposal Due: 10/5/17 Opp. Open until: 1/8/2018	Dependent upon application, for up to 5 years	Unrestricted	https://grants.nih.gov/grants/guide/pa-files/PA-14-142.html